Clinical Trials Sponsored by ViroXis Corporation

Total 6497 results

ViroXis Corporation

Terminated

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum

Molluscum Contagiosum

United States
ViroXis Corporation

Completed

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

Common Warts

United States
ViroXis Corporation
Progressive Clinical Research

Terminated

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

Condylomata Acuminata

United States
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Veloxis Pharmaceuticals

Completed

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) (STRATO)

Renal Failure | Tremors

United States
Vivoxid Ltd

Completed

Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

Spinal Fusion | Depressed Lateral Condyle Fracture | Benign Bone Tumour Cavity

Finland
Virogin Biotech Canada Ltd

Recruiting

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
Veloxis Pharmaceuticals

Completed

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Dyslipidemia

United States
Veloxis Pharmaceuticals

Completed

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Renal Failure

United States
Veloxis Pharmaceuticals

Approved for marketing

Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

Renal Failure
Veloxis Pharmaceuticals

Completed

Pharmacokinetic Comparison Of All FK-506 Formulations (ASTCOFF)

Renal Failure

United States
Veloxis Pharmaceuticals

Completed

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

Renal Failure

United States
Veloxis Pharmaceuticals

Recruiting

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Chemotherapy-induced Peripheral Neuropathy

United States, Japan
Veloxis Pharmaceuticals

Withdrawn

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

Chemotherapy-induced Peripheral Neuropathy
Veloxis Pharmaceuticals

Terminated

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Autoimmune Hepatitis

United States, Canada
Veloxis Pharmaceuticals

Completed

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Dyslipidemia

United States
Veloxis Pharmaceuticals

Completed

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (LCPTacro3002)

Renal Failure

United States, Argentina, Australia, Brazil, France, Germany, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Serbia, Singapore, Spain, Sweden
Virogin Biotech Canada Ltd

Recruiting

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Solid Tumor

United States
Shanghai Virogin Biotech Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China
Veloxis Pharmaceuticals
PPD

Completed

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Renal Failure

United States
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
CNBG-Virogin Biotech (Shanghai) Ltd.

Not yet recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Primary Hepatocellular Carcinoma
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumor

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Unknown

Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer

Primary Liver Cancer

China
Loyola University
Veloxis Pharmaceuticals

Recruiting

Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

Chronic Kidney Diseases | Heart Transplant

United States
Yale University
Veloxis Pharmaceuticals

Recruiting

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Kidney Transplant; Complications

United States
Columbia University
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Renal Transplant Rejection | Kidney Transplant Failure and Rejection

United States
Mayo Clinic
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus XR Compared to Immediate Release Tacrolimus (SIMPLE)

Kidney Transplant Recipients

United States
Temple University
Veloxis Pharmaceuticals

Completed

Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients

Kidney Transplant

United States
University of Wisconsin, Madison
Veloxis Pharmaceuticals

Recruiting

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

Kidney Pancreas Transplantation

United States
University of Michigan
Vironix Health Incorporated

Withdrawn

Emergency Department (ED) Self-Monitoring Pilot COVID-19

Covid-19 | SARS-CoV 2 | COVID
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
Roberto Gedaly
Veloxis Pharmaceuticals

Recruiting

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

End Stage Renal Disease

United States
University of Kansas Medical Center
Veloxis Pharmaceuticals

Completed

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus

End Stage Renal Disease

United States
Vanderbilt University Medical Center
Veloxis Pharmaceuticals

Recruiting

Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™ (OPERATOR)

Renal Transplant

United States
University of Southern California
Veloxis Pharmaceuticals

Recruiting

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (SIMPLE)

Kidney Transplantation | Kidney Transplant Rejection

United States
Cedars-Sinai Medical Center
Veloxis Pharmaceuticals

Active, not recruiting

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in HLA Sensitized Kidney Transplant Recipients

Kidney Transplant Rejection

United States
University of Colorado, Denver
Veloxis Pharmaceuticals

Terminated

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Kidney Transplant Rejection

United States
Sentara Norfolk General Hospital
Veloxis Pharmaceuticals

Completed

Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus (EVOKE-RT)

Transplant;Failure,Kidney

United States
Vanderbilt University Medical Center
Veloxis Pharmaceuticals

Enrolling by invitation

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Lung Transplant; Complications

United States
University of California, Davis
Veloxis Pharmaceuticals

Completed

A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients

Toxicity | Neurotoxicity | Kidney Transplant; Complications | Drug Toxicity

United States
University of Wisconsin, Madison
Veloxis Pharmaceuticals

Completed

Envarsus in Delayed Graft Function (E-DGF) (E-DGF)

Delayed Graft Function

United States
Albert Einstein Healthcare Network
Veloxis Pharmaceuticals

Active, not recruiting

Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant

Post Liver Transplant

United States
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services

Completed

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

Liver Failure

United States
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan

Clinical Trials Sponsored by ViroXis Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations